Podcasts about borla

Jeffrey abre su LAMY 2000 Pine y nos revela su reacción. ¿Qué estoy usando hoy?: LAMY 2000 Pine (F) Pelikan Edelstein Olivine  Tinterías Graf von Faber Castell Pen of the Year 2024 “Turquerie”  Kaweco Collection AL Sport Olivine 2024 Kaweco Classic Sport Black Piston Nahvalur Voyage Cookies & Cream Nahvalur Original Fall  Pilot Custom 742 Modernized Tradition Sailor Pro Gear Slim Dried Flower TWSBI Diamond 580ALR Caribbean con Onyx Tintería del capítulo: BORLA

Este jueves 14 de noviembre a las 20:00 horas Borla, Castazabal, El Drogas, Koma y Monte Del Oso subirán al escenario de ZENTRAL en un concierto solidario destinado a recaudar fondos. El sector musical se une en todo el país a través de SOM VALÈNCIA, una iniciativa nacida entre varias agentes del sector musical, que busca recaudar fondos que se destinarán íntegramente a los afectados

Olá, eu chamo-me José Alberto Macedo Silva, ou @josezerosilva nas redes, nasci no dia 24 de Setembro de 1993 e tenho TRINTA.TRINTA é uma ideia original de @josezerosilva.A foto da capa é da autoria de @mikes_dasilva.A música é "30" do Bo Burnham.Logótipo MEATO PODCASTS: @sararocha_dgMeato... fica no ouvido.Patreon: ⁠⁠www.patreon.com/oPutoDeBarba

Arrancamos esta mañana de lunes con nuestro turista musical que hoy viaja hasta Finlandia para conocer a Turisti. Continuamos con un bloque de música venido directamente de Euskadi como Etxepe, Eire o Borla. A las 8, la actualidad, y nos vamos hasta Mallorca para descubrir una nueva expresión regional: 'TÉNTOL' . Por último, hablamos sobre el colonialismo y la conquista de América con el actor, músico, escritor y viñetista, Víctor Coyote, que presenta su novela gráfica, en colaboración con el Museo Thyssen- Bornemisza, 'El Cóndor y la Caníbal'.Escuchar audio

This week on the pod, Larry has David Borla, of Borla Exhaust, on the pod to talk all things exhaust systems. Want to make more power? You've probably considered an aftermarket exhaust. Want better sound? You've probably considered an aftermarket exhaust. But, you've probably also wondered about drone and other objectionable frequencies. So, if you have thought about any of these exhaust-related things, David's got the info and answers in this conversation. Join the Hagerty Drivers Club! https://www.hagerty.com/drivers-club/ About the pod: the Never Stop Driving podcast is available on Itunes, Spotify, and YouTube. Like this newsletter, it's free to everyone because one of Hagerty's goals is to spread car passion. On the show, we'll cover a wide range of automotive topics, including interviews with the people doing the most interesting work in the car world. I expect it to evolve over time so your feedback is welcome. Please give it a listen and help us spread the word with a positive rating and share it.

El senador Rodrigo Borla, presidente de la Comisión de Análisis del Sistema Previsional, entregó el informe final sobre la reforma jubilatoria al ministro Fabian Bastía, destacando la necesidad de actuar rápido para salvar la Caja de Jubilaciones.

Hoy nos acompaña Roberto Schliesser para hablar de  Autos chinos, Borla Exhaust, Medio Oriente

Summary Erin Borla, Trustee and Executive Director of the Roundhouse Foundation, shares her journey into philanthropy and why she decided to focus on rural Oregon in this re-run episode. She explains how the needs of rural communities can differ from those of urban communities and how she developed a strategic initiative that supports rural philanthropy, including community food systems, disaster response, and early childhood education. Episode Highlights:The inspiring story of Erin's family.The opportunities to engage effectively with rural communities.The benefits of support for community engagement and its long-term impact.Erin Borla Bio:Erin Borla is the Executive Director and Trustee of The Roundhouse Foundation, and has worked in non-profit organizations that support rural communities through the arts and creative economies for the past 17 years. Her dedication to supporting rural spaces through listening, collaborating, and open and honest sharing of ideas helps her elevate community partners throughout her work. Borla holds a BS in Agriculture from Oregon State University and a Masters of Tourism Administration from The George Washington University. She has served organizations like Oregon State University – Cascades Campus, Sisters Parks & Recreation District, Central Oregon Regional Solutions Committee, Oregon 4 H Foundation, and others. She has served as a Trustee for the Sisters, Oregon based Roundhouse Foundation since 2014 and most recently stepped in as the organizations first Executive Director at a time of rapid growth for the Foundation.The Roundhouse Foundation supports innovative problem solving and creative solutions in four programmatic areas including arts and culture, environmental stewardship, education and social services throughout rural and tribal communities in Oregon.When she isn't exploring Oregon's unspoiled beauty, Erin enjoys spending time with her family, pets and reading.Links:The Roundhouse Foundation website: https://roundhousefoundation.org Funding Rural podcast: https://roundhousefoundation.org/funding-rural-podcastIf you enjoyed this episode, listen to these as well:https://podcasts.apple.com/us/podcast/171-strategies-to-leverage-federal-dollars-with-margi/id1556900518?i=1000649546992https://podcasts.apple.com/us/podcast/10-this-power-couple-explains-how-to-fund-effective/id1556900518?i=1000579747897https://podcasts.apple.com/us/podcast/20-think-outside-the-box-to-do-good-in-the-world/id1556900518?i=1000579747943Crack the Code: Sybil's Successful Guide to PhilanthropyBecome even better at what you do as Sybil teaches you the strategies and tools you'll need to avoid mistakes and make a career out of philanthropy.Sybil offers resources including free mini-course videos, templates, checklists, and words of advice summarized in easy to review pdfs. https://www.doyourgood.com/funders Check out Sybil's website with all the latest opportunities to learn from Sybil at https://www.doyourgood.comConnect with Do Your Goodhttps://www.facebook.com/doyourgoodhttps://www.instagram.com/doyourgoodWould you like to talk with Sybil directly?Send in your inquiries through her website https://www.doyourgood.com/ or you can email her directly at sybil@doyourgood.com.

Erin Borla, Trustee and Executive Director of the Roundhouse Foundation, shares her journey into philanthropy and why she decided to focus on rural Oregon in this re-run episode. She explains how the needs of rural communities can differ from those of urban communities and how she developed a strategic initiative that supports rural philanthropy, including community food systems, disaster response, and early childhood education. {You can hear the full episode on Monday, June 17th}

Holly Borla: Swift Language Engineering Manager @holly on Mastodon Ben Cohen: Senior Software Engineering Manager, Swift Team @airspeedswift on Mastodon

Devocional Cristiano para Jóvenes - COMPLETAMENTE AL AZAR Fecha: 03-06-2024 Título: LA BORLA Autor: Olivia Cold Locución: Ale Marín http://evangelike.com/devocionales-cristianos-para-jovenes/

Joining Jarod today is David Borla. David is the Chief Marketing Officer for Borla Performance. Borla is the originator of aftermarket performance exhaust systems. In today's episode, they discuss the future of Borla and how they are entering into the EV space, and how they plan to make driving an EV even more enjoyable.

This week we had the opportunity to talk to Holly Borla who manages the Swift Compiler Team at Apple. We chat about upcoming Swift 6 changes and why they're a big deal, but also why you shouldn't worry too much. Of course, all three of us pick packages, too!Interview with HollySE-0414: Region isolation SE-0431: Dynamically isolated function typesPackagesGRDB by Gwendal RouéGwendal's forum thread about adding Sendable annotationsPack by Matt CoxGeoURI by Jeff JohnstonConcurrencyRecipes by Matt Massicottegenerative-ai-swift by GoogleFit by Oleh Korchytskyi

A história do João Pedro Pais, o cantor de sorriso triste a quem a vida nada deu de borla

Japan hosted its annual Toky Auto Salon event and the headline widebody Lamborghini Countach was a showstopper. - Dodge teases the production Charger in its rightful Coupe form. - Mustang Mach-E owners get love from Borla... an exhaust company, Toyota releases the new GR Yaris, and Ford teases the future of offroading. - Along with Mazda announcing the official development of a renowned engine engine. - Sit back, relax, and enjoy... this is CarQuicks! - #CarQuicks #CarQuicksPodcast #Podcast #Episode42 #TAS2024 #Tokyoautosalon2024 #TokyAutoSalon #Toyota #GazooRacing #GRYaris #GRCorolla #JDM #aftermarket #Borla #Varis #Cusco #Greddy #HKS #GROWMotorsports #BMW #RX7 #RocketBunny #Blitz #Ford #FordPerformance #FordLightning #LightningSwitchGear #SwitchGear #FordSwitchGear #Recaro #Lamborghini #LamborghiniCountach #LibertyWalk #Aimgain #Dodge #DodgeCharger #ChargerEV #Charger #HurricanInline6 #Mustang #MustangMachE #Mazda #RotaryEngine - 00:00 Introduction 00:57 Ford Lightning SwitchGear 05:29 Mazda Announces Rotary Engine Development 11:21 Dodge Charger Coupe 15:10 Borla Release an Exhaust for the Mustang Mach-E? 19:47 Tokyo Auto Salon 2024 Thoughts 32:07 Tokyo Auto Salon GR Corolla 33:17 Toyota Releases the Redesigned 2024 GR Yaris 36:18 GR Corolla Updates | New Parts to Install 38:19 Future Podcast Ideas | Outro

Merry Christmas and Happy Holidays to everyone! Our long, lost Megan returns to us to join us for Shop Talk this week and we talk all about squashing nuts, the new studio, Borla's electric "exhaust", R8 build updates, and our very adult Christmas lists! Also, if anyone is selling a BAC Mono, let Dan know. 

In questo episodio del podcast della Rivista di Psicoanalisi, Laura Ravaioli ospita il presidente della Società Psicoanalitica Italiana, Sarantis Thanopulos, approfondendo il suo contributo “L'empirico e l'esperienza” pubblicato come 'intervista a cura del collega di redazione Riccardo Galiani nel vol.2/2023 della Rivista.Sarantis Thanopulos, psicoanalista ordinario con funzioni di training della SPI, vive e lavora a Napoli. La sua ricerca in campo psicoanalitico riguarda principalmente i disturbi psichici e le forme di psicosi, le manifestazioni del desiderio, il rapporto tra tragedia e psicoanalisi, e questi argomenti sono il tema delle sue molte pubblicazioni, tra cui ricordiamo:Lo spazio dell'interpretazione, Borla, Roma 2009Psicoanalisi delle psicosi. Prospettive attuali (con R. Lombardi, L. Rinaldi), Raffaello Cortina, Milano 2016.Il diavolo veste ISIS. Lo straniero di casa. Asterios, 2018.La solitudine della donna. Quodlibet, 2018.Il desiderio che ama il lutto. Quodlibet, 2016

Erin Borla, Trustee and Executive Director of the Roundhouse Foundation, shares her journey into philanthropy and its focus on rural Oregon. Erin is passionate about explaining how the rural community needs that can differ from those of urban communities. She shares how she developed a strategic initiative that supports rural philanthropy, including community food systems, disaster response, and early childhood education. Episode Highlights:The inspiring story of Erin's family.The opportunities to support rural communities.The benefits of community engagement and its long-term impact.Erin Borla Bio:Erin Borla is the Executive Director and Trustee of The Roundhouse Foundation, and has worked in non-profit organizations that support rural communities through the arts and creative economies for the past 17 years. Her dedication to supporting rural spaces through listening, collaborating, and open and honest sharing of ideas helps her elevate community partners throughout her work. Borla holds a BS in Agriculture from Oregon State University and a Masters of Tourism Administration from The George Washington University. She has served organizations like Oregon State University – Cascades Campus, Sisters Parks & Recreation District, Central Oregon Regional Solutions Committee, Oregon 4 H Foundation, and others. She has served as a Trustee for the Sisters, Oregon based Roundhouse Foundation since 2014 and most recently stepped in as the organizations first Executive Director at a time of rapid growth for the Foundation.The Roundhouse Foundation supports innovative problem solving and creative solutions in four programmatic areas including arts and culture, environmental stewardship, education and social services throughout rural and tribal communities in Oregon.When she isn't exploring Oregon's unspoiled beauty, Erin enjoys spending time with her family, pets and reading.Links:Round House Foundation website: https://roundhousefoundation.org If you enjoyed this episode, listen to these as well:https://www.doyourgood.com/blog/150-pooled-funds-that-protects-sharkshttps://www.doyourgood.com/blog/57-michael-chatmanhttps://www.doyourgood.com/blog/156-Supporting-the-Places-that-Rejuvenate-You-with-Dana-OkanoCrack the Code: Sybil's Successful Guide to PhilanthropyBecome even better at what you do as Sybil teaches you the strategies and tools you'll need to avoid mistakes and make a career out of philanthropy.Sybil offers resources including free mini-course videos, templates, checklists, and words of advice summarized in easy to review pdfs. Check out Sybil's website with all the latest opportunities to learn from Sybil at https://www.doyourgood.comConnect with Do Your Goodhttps://www.facebook.com/doyourgoodhttps://www.instagram.com/doyourgoodWould you like to talk with Sybil directly?Send in your inquiries through her website https://www.doyourgood.com/ or you can email her directly at sybil@doyourgood.com.

Erin Borla, Trustee and Executive Director of the Roundhouse Foundation, shares her journey into philanthropy and its focus on rural Oregon. Erin is passionate about explaining how the rural community needs that can differ from those of urban communities. She shares how she developed a strategic initiative that supports rural philanthropy, including community food systems, disaster response, and early childhood education. {You can hear the full episode on Monday December 4th}

MILANO (ITALPRESS) - "Il programma Women Value Company è importante perchè la sensazione è che per il mondo del femminile sia già stato fatto tutto, che la parità sia stata pienamente raggiunta. Poi vediamo i dati, vediamo i delta salariali, ci accorgiamo che ancora molto è da fare". A dirlo Virginia Borla, Responsabile Business Governance Banca dei Territori di Intesa Sanpaolo, in occasione del terzo evento conclusivo del premio Women Value Company a Milano.f01/fsc/gsl

NAPOLI (ITALPRESS) - "E' fondamentale che ogni persona possa dare il proprio valore all'interno dell'azienda e della società". Lo dice Virginia Borla, responsabile Business Governance Banca dei Territori di Intesa Sanpaolo, a margine del il secondo evento conclusivo del premio Women Value Company Intesa Sanpaolo, organizzato dal Gruppo bancario in collaborazione con Fondazione Marisa Bellisario.col/sat/gsl

NAPOLI (ITALPRESS) - Nel 2022 l'Italia si è collocata all'ultimo posto tra i paesi europei per tasso di attività femminile, 13 punti in meno rispetto alla media dell'Unione. Su questo risultato pesano soprattutto i ritardi delle regioni del Mezzogiorno. Se l'Italia si allineasse al valore medio europeo di attività femminile, significherebbe un incremento di 2,4 milioni nella forza lavoro, con effetti positivi sulla crescita del PIL. Si è parlato anche di questi dati a Napoli, per il secondo evento conclusivo del premio Women Value Company Intesa Sanpaolo, organizzato dal Gruppo bancario in collaborazione con Fondazione Marisa Bellisario. col/sat/gsl

NAPOLI (ITALPRESS) - Nel 2022 l'Italia si è collocata all'ultimo posto tra i paesi europei per tasso di attività femminile, 13 punti in meno rispetto alla media dell'Unione. Su questo risultato pesano soprattutto i ritardi delle regioni del Mezzogiorno. Se l'Italia si allineasse al valore medio europeo di attività femminile, significherebbe un incremento di 2,4 milioni nella forza lavoro, con effetti positivi sulla crescita del PIL. Si è parlato anche di questi dati a Napoli, per il secondo evento conclusivo del premio Women Value Company Intesa Sanpaolo, organizzato dal Gruppo bancario in collaborazione con Fondazione Marisa Bellisario. col/sat/gsl

NAPOLI (ITALPRESS) - "E' fondamentale che ogni persona possa dare il proprio valore all'interno dell'azienda e della società". Lo dice Virginia Borla, responsabile Business Governance Banca dei Territori di Intesa Sanpaolo, a margine del il secondo evento conclusivo del premio Women Value Company Intesa Sanpaolo, organizzato dal Gruppo bancario in collaborazione con Fondazione Marisa Bellisario.col/sat/gsl

#Mañana967

#Mañana967

In questo episodio Laura Ravaioli intervista Giuseppe Martini, curatore con Maria Pierri e Stefania Romano del Focus sulla Guerra, pubblicato sul vol.1/2023 della Rivista di Psicoanalisi.Giuseppe Martini è psicoanalista della Società Psicoanalitica Italiana; già primario psichiatra del Dipartimento di Salute Mentale Roma 1, ha insegnato presso le Scuole di specializzazione in Psichiatria di diverse Università italiane. Campo elettivo della sua attività clinica sono le depressioni, i disturbi di personalità, le psicosi, l'integrazione tra trattamento farmacologico e psicoterapico; in ambito teorico si interessa dei rapporti tra psicoanalisi e filosofia ermeneutica, psicoanalisi e cinema, psichiatria e narrazione. E' autore di circa 180 pubblicazioni e di cinque volumi: Ermeneutica e Narrazione (Bollati Boringhieri, Torino, 1998), La sfida dell'Irrappresentabile (Franco Angeli, Milano, 2005), La psicosi e la rappresentazione (Borla, Roma, 2011), Le storie infrante, un romanzo (Ed. Fattore Umano, Roma, 2016) e L'identità in questione, quest'ultima in collaborazione con il filosofo Vinicio Busacchi (Jaca, Milano, 2020).Approfondimenti nella Rivista di PsicoanalisiBonasia, E. (2001) La guerra, la morte e il figlicidio. Rivista di Psicoanalisi 47:303-318Rossi, P. L. (2008) Lo spavento, la guerra e la cultura della paura. Rivista di Psicoanalisi 54:657-672Semi, A. A. (1992) Patrizia Messeri and Elena Pulcini (eds). Immagini dell'impensabile. Ricerche interdisciplinari sulla guerra nucleare. Marietti, Genova, 1991, 246 pages, 38.000 lire.. Rivista di Psicoanalisi 38:284-290Zerbino, E. (1996) Carlo Battaglia (1994) Psicologia e guerra nel Novecento Edizioni Cultura della Pace, Firenze, 126 pagine, 22.000 Lire.. Rivista di Psicoanalisi 42:179-180Bolognini, S. (2005) Patrizia Brunori, Gianna Candolo, Maddalena Donà dalle Rose, Maria Chiara Risoldi Traumi di guerra. Un'esperienza psicoanalitica in Bosnia Erzegovina Ed. Manni, S. Cesario di Lecce, 254 pagine, euro 15,00. Rivista di Psicoanalisi 51:250-253

Senador por San Justo

Escuchá #Mañana967 de lunes a viernes de 9 a 12 por Radio GOL FM 96.7 y www.radiogol.com.ar

Edição de 29 de Novembro 2022

The guys bring you all the newness from the 2022 SEMA Show from top brands like Borla, Cerakote, Wilwood, TMI Products, Bilstein, HP Tuners (with a Gozilla'd Raptor bonus), and Nissan, with a cameo from the Motorator himself, Matt D'Andria.

JJ's wife makes a special appearance in this episode, after a couple of glasses of Pinot Grigio... Mikie's week Aly on KSHU We hit the 1 year mark! Poker nights - need to happen again "Face It Alone" track from Queen Political spam and texts Mikie getting Medicare calls False advertising - politicians "Andor" series  Televised lidocaine - Leslie Uncle Haji - Dirtiest man in the world Recall on big rig trucks for LED displays F-250 Intakes Ford (and Borla) putting audible exhaust on Mustang E-GT Kia recall - again Nascar driver takes outside wall to close gap for qualify Peruvian police dress up as MCU characters for drug bust Malta man - "Kiss My Balls" Outro: AngerShade - "Envy" AngerShade music can be found on all popular streaming platforms. Contact: Email: sauce@tacojohnnypodcast.com Discord: taco_johnny Twatter: @tacojohnnypod Insta: Taco_Johnny_Podcast Thank you for listening and subscribing!

De los que nos enteramos viendo la TV, Suzuki Jimny con Borla, Nissan y su nuevo Versa 2023, Sev E Wan el eléctrico mas barato, Yaris Sedan 2023

Link all'articolo: https://riviste.raffaellocortina.it/scheda-articolo_digital/maurizio-balsamo/necessita-e-finzione-dellapres-coup-RDPS2022_2_3-3776.htmlLink al volume 2/2022: https://riviste.raffaellocortina.it/scheda-fascicolo_contenitore_digital/autori-vari/rivista-di-psicoanalisi-2022-2-RDPS2022_2-3773.htmlIl lavoro propone una distinzione fra processi in après-coup che utilizzano il dispiegamento rappresentativo, permettendo l'espansione e la trasformazione del senso, e altri che difettano di questa possibilità, «ruotando» intorno all'asse della ripetizione non trasformativa. In tali casi il difasismo scenico, la costruzione di una nuova scena atta a rappresentare/simbolizzare il primo colpo, fallisce nel suo compito e si dispiega allora un trattamento – nel reale – del trauma primario. Il caso clinico di un paziente grave e della sua invenzione delirante permette di approfondire l'estrema difficoltà di istituire, nell'analisi, un'altra scena e di aprire uno spazio associativo, che in quanto tale trasporterebbe con sé il ricordo e il confronto con il trauma. L'oscillazione metaforo-metonimica, propria ai processi psichici, si piega in tali casi dal solo lato della concretezza, della fobia del pensiero, della permanenza nell'inamovibile.Nell'episodio odierno Maurizio Balsamo, viene intervistato da Gaetano Pellegrini sui contenuti al centro del suo articolo, pubblicato sul volume 2/2022 della Rivista di Psicoanalisi.Maurizio Balsamo è psichiatra, psicoanalista con funzioni di Training della Società psicoanalitica italiana, ha conseguito un phd in psicopatologia psicoanalitica nell'Università di Parigi 7 ed è stato, dal 2005 al 2020, Maître de conférences- Direttore di ricerca nell'Università di Parigi / Denis Diderot. È stato segretario scientifico del centro psicoanalitico di Roma, segretario della seconda sezione romana di Training, e Vicepresidente dell'associazione Internazionale di Storia della psicoanalisi. Ha diretto la rivista interdisciplinare Psiche, edita dal Mulino, dal 2014 al 2018, e dirige ora con Massimo Recalcati la rivista Frontiere della psicoanalisi sempre per le edizioni de Il Mulino. Dirige inoltre la collana “Le vie della psicoanalisi” (Franco Angeli). Ha fondato con altri colleghi l'associazione di ricerca psicoanalitica Clinamen.Principali Pubblicazioni:* (2019), M. Balsamo, André Green, Feltrinelli, Milano* (2019), M. Balsamo, Ascoltare il presente, Mimesis, Milano * (2015) M. Balsamo (a cura di), L'autobiografia psicotica, FrancoAngeli, Milano* (2014) M. Balsamo, (a cura di), Momenti psicotici nella cura, FrancoAngeli, Milano* (2011) M. Balsamo, (a cura di), Libere associazioni?, FrancoAngeli, Milano* (2010) M. Balsamo, Psychanalyse et subjectivité , Ed. Campagne première, Paris* (2009) M. Balsamo, (a cura di), Forme dell'après-coup, FrancoAngeli, Milano* (2009) M. Balsamo, (a cura di) Psiche e Storia, FrancoAngeli, Milano* (2008) M. Balsamo (a cura di), La regressione nella stanza d'analisi, Franco Angeli, Milano* (2004) M. Balsamo, Freud, Mondadori, Milano (traduzione spagnola, greca, tedesca, francese, inglese)* (2000) M. Balsamo, Freud et le destin, Puf, Paris.* (2000) M. Balsamo (a cura di), Soggetti al delirio, Franco Angeli, Milano.* (2000) M. Balsamo (a cura di), Analisi curabile e incurabile, Franco Angeli, Milano.* (1998) M. Balsamo et F. Napolitano, Freud, Lei e l'altro, Franco Angeli, Milano.* (1998) M. Balsamo, (a cura di) Sessuale, destino, scrittura, Franco Angeli, Milano. * (1994) M. Balsamo et F. Napolitano, Costruire e ricostruire, Borla, Roma.

Mike Timmons and Pat Johnson from EGR USA come to the studio to tell the guys about their killer new Rolltrac smart tonneau cover, Lightning has been busy with truck upgrades, and we have an update to share on Mike Seibold's New Jersey emissions drama.

Renault e-tech, Borla hará sonar a los autos electricos, los 5 autos más baratos en México.

Adam and Matt are joined by David Borla, the VP of Sales & Marketing at Borla Performance Industries. They talk to David about the process of designing and manufacturing of stainless steel performance exhaust and get into their recent penalty issued by the EPA.

Adam and Matt are joined by David Borla, the VP of Sales & Marketing at Borla Performance Industries. They talk to David about the process of designing and manufacturing of stainless steel performance exhaust and get into their recent penalty issued by the EPA.

The recently signed gun law, S. 2938: Bipartisan Safer Communities Act, contained a surprise dingleberry postponing a regulation designed to save seniors money on their pharmaceutical drugs by prohibiting kickbacks to an industry few have heard of: Pharmacy Benefit Managers (PBMs). This little-known but extremely powerful industry deserves much of the blame for ever rising prescription drugs costs in the United States. In this episode, Jen gives you the scoop on PBMs and how they make their money at the expense of Americans who are most dependent on medications. Please Support Congressional Dish – Quick Links Contribute monthly or a lump sum via PayPal Support Congressional Dish via Patreon (donations per episode) Send Zelle payments to: Donation@congressionaldish.com Send Venmo payments to: @Jennifer-Briney Send Cash App payments to: $CongressionalDish or Donation@congressionaldish.com Use your bank's online bill pay function to mail contributions to: 5753 Hwy 85 North, Number 4576, Crestview, FL 32536. Please make checks payable to Congressional Dish Thank you for supporting truly independent media! View the shownotes on our website at https://congressionaldish.com/cd255-pharmacy-benefit-managers-pbms We're Not Wrong Berlin Meetup Contact Justin at WereNotWrongPod@gmail.com Background Sources Recommended Congressional Dish Episodes CD134: The EpiPen Hearing US Healthcare Landscape Jessi Jezewska Stevens. Apr 23, 2020. “A Brief History of the Great American Healthcare Scam.” Bookforum. Tanza Loudenback. Mar 7, 2019. “The average cost of healthcare in 21 different countries.” Insider. Chuck Grassley and Ron Wyden. 2019. “Insulin: Examining the Factors Driving the Rising Cost of a Century Old Drug [Staff Report].” U.S. Senate Finance Committee. “Health Insurance Coverage of the Total Population.” Kaiser Family Foundation. Sara R. Collins and David C. Radley. Dec 7, 2018. “The Cost of Employer Insurance Is a Growing Burden for Middle-Income Families.” The Commonwealth Fund. PBMs What are PBMs? JC Scott. Jun 30, 2022. “Drug manufacturers are root cause of high drug costs; PBMs drive costs down.” The Hill. Zach Freed. Jun 22, 2022. “The Pharmacy Benefit Mafia: The Secret Health Care Monopolies Jacking Up Drug Prices and Abusing Patients and Pharmacists.” American Economic Liberties Project. Adam J. Fein. Jun 22, 2021. “The Top Pharmacy Benefit Managers of 2020: Vertical Integration Drives Consolidation (rerun).” Drug Channels. “Flash finding: How drug money from sick people really works.” Nov 11, 2021. 46brooklyn. Adam J. Fein. Feb 3, 2019. “Don't Blame Drug Prices on ‘Big Pharma.'” The Wall Street Journal. How PBMs Make Money “DIR Fees.” National Association of Chain Drug Stores. “How PBMs Make Money: PBM Practices & Profits.” RxSafe. True North Political Solutions. Oct 25, 2017. “White Paper: DIR Fees Simply Explained.” Pharmacy Times. ACA “Vertical Integration” Loophole Peter High. Jul 8, 2019. “A View From Inside Cigna's $67 Billion Acquisition Of Express Scripts.” Forbes. Angelica LaVito. Nov 28, 2018. “CVS creates new health-care giant as $69 billion merger with Aetna officially closes.” CNBC. David Dayen. Oct 12, 2018. “Why the Aetna and CVS Merger Is So Dangerous.” The American Prospect. Jeff Byers. April 12, 2018. “Optum a step ahead in vertical integration frenzy.” Healthcare Dive. Graph: Optum opens up wider market for UnitedHealth Group Graph: Optum's pharmacy business contributes the majority of its revenue Susan Morse. May 10, 2017. “Secret weapon: UnitedHealth's Optum business is laying waste to old notions about how payers make money.” Healthcare Finance. Lobbying “Client Profile: Pharmaceutical Care Management Assn.” Open Secrets. The Demise of Independent Pharmacies Christine Blank. Oct 17, 2019. “Independents Prepare to Close Up Shop.” Drug Topics. Paulina Firozi. Aug 23, 2018. “The Health 202: Here's why rural independent pharmacies are closing their doors.” The Washington Post. What Is a Formulary? Ana Gascon Ivey. May 19, 2020. “A Guide to Medication Formularies.” GoodRx. Previous Delays in Rebate Regulation Paige Minemyer. Jan 29, 2021. “In a win for PBMs, Biden administration delays rebate rule.” Fierce Healthcare. Paige Minemyer. Jan 12, 2021. “PCMA sues Trump administration over rebate rule.” Fierce Healthcare. “Incorporating the Effects of the Proposed Rule on Safe Harbors for Pharmaceutical Rebates in CBO's Budget Projections—Supplemental Material for Updated Budget Projections: 2019 to 2029.” May 2019. Congressional Budget Office. The Gun Law Passage Process Office of the Clerk. May 18, 2022. “Roll Call 212 | Bill Number: S. 2938.” U.S. House of Representatives. Tampa Bay Times Editorial Board. May 12, 2022. “Republican lawmakers should be ashamed for failing to honor Justice Joseph Hatchett.” Miami Herald. Annie Karni. Apr 12, 2022. “House G.O.P., Banding Together, Kills Bid to Honor Pioneering Black Judge.” The New York Times. Background on Most Important Provisions Mary Katherine Wildeman. May 26, 2022. “Data show most school shootings carried out by young adults, teens.” CT Insider. Jeffrey Pierre. May 26, 2022. “Experts say we can prevent school shootings. Here's what the research says.” NPR. The Dingleberry Erik Sherman. Jun 30, 2022. “Gun Safety Bill Extends Drug Middlemen Protection From Anti-Kickback Measure.” Forbes. Molly Rutherford. Jun 28, 2022. “Gun legislation provision puts drug supply chain profits over patients.” The Hill. Marty Schladen. Jun 22, 2022. “Deep inside the gun bill: a break for prescription drug middlemen.” Iowa Capital Dispatch. Poland Train Station Taylor Popielarz, Maureen McManus and Justin Tasolides. Mar 25, 2022. “‘The help given is remarkable': Inside the Poland train station that's become a hub for Ukrainian refugees.” Spectrum News NY1. The Law and the Regulation S. 2938: Bipartisan Safer Communities Act Senate Vote: 65-33 (All Nos GOP) House Vote: 234-193 (All Nos GOP) Jen's Highlighted PDF of S. 2938: Bipartisan Safer Communities Act Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees U.S. Health and Human Services Department November 30, 2020 Audio Sources The State of Competition in the Pharmacy Benefits Manager and Pharmacy Marketplaces November 17, 2015 House Committee on the Judiciary Witnesses: Bradley J. Arthur, R.Ph., Owner, Black Rock Pharmacy David Balto, Law Offices of David A. Balto PLLC Amy Bricker, R.Ph. Vice President of Retail Contracting & Strategy, Express Scripts Natalie A. Pons, Senior Vice President and Assistant General Counsel, CVS Health Clips 53:48 Bradley Arthur: The Big Three PBMs control almost 80% of the entire market and these PBMs have the upper hand both in negotiating the contract with the payer, as well as strongly influencing the actual plan design itself. The PBM industry typically states that they can use their economic power to harness enhanced market efficiencies, but for whom? However, the staggering annual revenues that continue to grow each year of the big three suggests that these efficiencies are going directly to their corporations' bottom lines. Small community pharmacies like mine are faced on a daily basis with the impact of the PBMs' disproportionate market power. Community pharmacies routinely must agree to take-it-or-leave-it contracts from the PBMs just to continue to serve our long-standing patients. As if that weren't enough, the PBMs also directly set the reimbursement rates for pharmacies, the very same pharmacies that stand in direct competition of some of these PBM-owned mail-order and specialty pharmacies. Therefore, it comes as no surprise that the PBMs present employer and government payers with carefully tailored suggested plans designs that steer beneficiaries to these PBM-owned entities. Drug Pricing in America: A Prescription for Change, Part I January 29, 2019 Senate Committee on Finance Witnesses: Kathy Sego, Mother of a Child with Insulin-Dependent Diabetes Douglas Holtz-Eakin, Ph.D., President, American Action Forum Mark E. Miller, Ph.D., Vice President of Health Care, Laura and John Arnold Foundation Peter B. Bach, MD, MAPP, Director, Memorial Sloan Kettering Center for Health Policy and Outcomes Clips 1:57:30 Sen. John Cornyn (R - TX): Can anybody on the panel explain to me why we have a general prohibition against kickbacks — they call them rebates — under the Social Security Act, but we nevertheless allow it for prescription drug pricing? What's the sound public policy reason for excluding prescription drug pricing from the anti-kickback rule under federal law? Douglas Holtz-Eakin: I can't explain that and won't pretend to. [laughter] Sen. Cornyn: I thought I was the only one who didn't understand the wisdom of that. Well, it's not a transparent arrangement and it does produce upward pressure on drug prices. And obviously, the negotiations between the PBM and the pharma in terms of what the net cost is, is not transparent, nor is it delivered to the consumer. Is it Dr. Miller? Dr. Bach? Peter Bach: It's delivered to the consumer indirectly through the reduction of the total cost of the benefit, but it is not delivered to the actual consumer using the drug, and that is a disassociation, that is a problem. Because it essentially reverses the structure of insurance. Lowering the total costs are people who use it the least, and raising the costs are people who use it the most, relative to if you allowed the rebate to be used at the point of sale, including all discounts. 1:59:49 Douglas Holtz-Eakin: If we had the negotiation be about the upfront price, so instead of a high list price and a rebate, you just negotiate a lower price, that would be the price that Ms. Sego would pay and insurance companies would look at that and say, okay, she's not paying as much as she used to, we're going to have to make up that money somewhere else and they might raise premiums. That means that people who don't have extreme insulin drug costs would pay a little bit more in a premium every month, and people who have extremely devastating medical conditions and high health care costs would get less costs. That's exactly what insurance is supposed to do. And so the rebate system is more than giving strange incentives on pricing. It's undercutting the purpose of insurance in general. Drug Pricing in America: A Prescription for Change, Part II February 26, 2019 Senate Committee on Finance Witnesses: Richard A. Gonzalez, Chairman and Chief Executive Officer, AbbVie Inc. Pascal Soriot, Executive Director and Chief Executive Officer, AstraZeneca Giovanni Caforio, M.D., Chairman of the Board and Chief Executive Officer, Bristol-Myers Squibb Co. Jennifer Taubert, Executive Vice President, Worldwide Chairman, Janssen Pharmaceuticals, Johnson & Johnson Kenneth C. Frazier, Chairman and Chief Executive Officer, Merck & Co., Inc. Albert Bourla, DVM, Ph.D., Chief Executive Office, Pfizer Olivier Brandicourt, M.D., Former Chief Executive Officer, Sanofi Clips 1:22:03 Albert Bourla: Adverse incentives that favor higher cost biologics are keeping biosimilars from reaching patients. In many cases, insurance companies declined to include lower cost biosimilars in their formularies because they would risk losing the rebates from covering higher cost medicines. I can't think of a more concerning example of a broken system and we need to do something about it. 1:33:35 Sen. Chuck Grassley (R - IA): So many of you have voiced support for the recent rebate rule proposed by the administration. Should the administration finalized this rule, will you commit to lowering your drug prices? Richard Gonzalez [CEO, AbbVie]: Mr. Chairman, we are supportive of the rule. We'd like to see it in its final form, obviously, to make a final decision, but we are supportive of taking the discount to the patient at the point of sale. Sen Grassley: Okay. AstraZeneca? **Pascal Soriot [CEO, AstraZeneca]**The same for us Senator, I would go one step further: if the rebates were removed from the commercial sector as well, we will definitely reduce our list prices. Sen Grassley: Okay. And Bristol? Giovanni Caforio [CEO, Bristol-Myers Squibb]: We have the same positions. Sen Grassley: Okay. Johnson and Johnson? Jennifer Taubert [EVP, J&J]: Yes, we're supportive, and that definitely would be my goal. We would just need to see the final legislation, provided that there aren't additional fees that are added into the system to compensate for the rebates. Sen Grassley: Merck? **Kenneth C. Frazier: I would expect that our prices would go down if we change the system. Again, on the commercial side as well as the Medicare side. Sen Grassley: Okay, Pfizer? Albert Bourla [CEO, Pfizer]: It is a very clear intention that we will not keep a single dollar from these rebates. We will try to move every single penny to the patients and we think if this goes also to the commercial plants that will be even better for more patients. Sen Grassley: Okay. Sanofi? Olivier Brandicourt [Former CEO, Sanofi]: Lowering list price has to be linked to better access and affordability at the counter for the patients. 1:35:20 Sen. Ron Wyden (D - OR): Is it correct that your company, and nobody else, sets the starting price for all drugs sold by Pfizer? Yes or no? Albert Bourla: It is a negotiation with PBMs and they are very powerful. Sen. Wyden: But you still get to set the list price? Albert Bourla: Yes, but we set this price and the rebate limit(?). 1:35:40 Sen. Ron Wyden (D - OR): Is it correct, when a hypothetical patient, let's call her Mrs. Jones, goes to pay for her drug at the pharmacy counter, her coinsurance is based on the price of the drug you set? Albert Bourla: It is correct in many cases. Sen. Wyden: Okay. I just want you all to know that the number one reason consumers are getting hammered, is because these list prices, which you have the last word with respect to where they are, are unaffordable. And the high prices are tied to what the consumer pays at the pharmacy counter. And all this other stuff you talk about, the rebates and the discounts and the coupons, all this other stuff is window dressing, all of that. And the fact is on Part D, 40% of the drugs don't even have a rebate. So I want it understood, particularly because I've asked you, Mr. Borla, I think you and others in the industry are stonewalling on the key issue, which is actually lowering list prices. And reducing those list prices are the easiest way for American consumers to pay less at the pharmacy counter. 2:12:45 Sen. Thomas Carper (D-DE): First is eliminating rebates to PBMs. That's the first one, eliminating rebates to PBMs. The second is value based arrangements. And the third is increasing transparency industry-wide on how you set your prices. 2:13:20 Richard Gonzalez: We clearly support providing the discount at the patient level, eliminating rebates essentially. 2:14:10 Pascal Soriot: If the rebates, as I said earlier, were to be removed from Part D and the commercial sector, we would actually reduce our list prices. 2:15:10 Giovanni Caforio: I would say that not only do we support all three elements that you mentioned, but I do believe those three elements together with the continued effort to develop a generic and biosimilar market would mean significant change, and would clearly alleviate the concerns that patients have today. 2:14:44 Jennifer Taubert: We are very supportive of all three elements that you outlined 2:15:52 Kenneth Frazier: We too support all three. 2:15:55 Albert Bourla: All three elements are transformational for our industry, will disrupt it. However, we do agree that these are the three things that need to be done and also I believe that will have significant meaningful results if we do. 2:16:10 Olivier Brandicourt: We support the three Senator, but we want to keep in mind at the end of the chain the patient has to benefit, so if rebates are removed it has to be to the benefit of patients. Sen. Thomas Carper (D-DE): Good, thanks. 2:18:10 Albert Bourla: 50% of the American people are in commercial plans and these rebate rules apply to Medicare. If the rules apply to all, definitely the list price will go down. 2:18:30 Albert Bourla: The list price is not irrelevant, it's very relevant for a lot of people because they have to pay list price during the deductible period. However if the rebate rule is applied, then they become irrelevant because the patients will not be paying the list price at the purchase point. 2:19:10 Sen. John Thune (R-SD): How would manufacturers respond if the rebate rule were finalized for government programs? I mean, what does that what does that mean for the commercial market? Albert Bourla: Senator, as I said before, all these proposals that they're discussing, [undistinguishable], eliminating the rebate rule, are transformational and will disrupt the way we do business. I don't know exactly how the system will evolve, and I really don't favor a bifurcated system. I would like to have a transparent single system across both parts. So we need to see how the whole thing will evolve. 2:25:26 Johnny Isakson (R-GA): Who sets the discount and who sets the rebate? 2:26:20 Richard Gonzalez: We negotiate with payers, so managed care and PBMs— Sen. Johnny Isakson (R-GA): You're a supplier though, so you have to go negotiate with the PBMs and those people, is that right? Richard Gonzalez: Correct, and they negotiate aggressively. Sen. Isakson: Is that pretty much true with everybody, that they're the major component between the end retail consumer price and the origin of the product? Richard Gonzalez: Yes, Senator. Sen. Isakson: Well, that seems like that's someplace we ought to focus, because that's where the distorted numbers come in. Johnson & Johnson, Janssen, in your testimony, you talked about your average list price of 8.1%, up, but an average net price change of only 4.6%. So while your gross went up 8.6, your net went down 4.6 In the same pricing period. How does that happen? If you're setting the price, how does it not go up on the bottom? Jennifer Taubert: Yeah, and in fact, in 2018, our net price actually declined 8.6%, so even more than that. The intermediaries in the system are very, very effective negotiators— Sen. Isakson: Tell me who the intermediaries are. Jennifer Taubert: Those would be the PBMs and the insurers. Sen. Isakson: …and the insurance companies? Jennifer Taubert: Right, and they set the formularies for patients. Sen. Isakson: And they're not the same. They're two different people? Jennifer Taubert: Yes, correct. 2:40:45 James Lankford (R-OK): All of you have mentioned the rebate issue has been a problem and that insurance companies and PBMs are very effective negotiators. Part of the challenge of this is, health insurance companies pay their PBM based on the quality of their negotiation skills, cutting a price off the list price. And so if a list price is higher and a rebate is higher, that also gives preference to them. So the difficulty is, as you raise list price, and the rebate gets larger, the insurance company gives that preference, making it harder for biosimilars. Am I tracking this correctly? 2:43:00 Albert Bourla: Here in the US, the penetration of biosimilars is much lower than in other places, but it is disproportional to different parts of the US healthcare system. For example, in open systems, systems where the decision maker it is a PBM, the one biosimilar we have has a market share of 5% in the US. In closed systems, in systems like Kaiser, for example, integrated healthcare systems where the one who decides has the whole cost of the healthcare system in its interest, we have 73%. 5% and 73% for the same product. I agree with what Mr. Fraser said that we need to create incentives, but I would add also that we need to break this rebate trap that creates significant disincentives for providers, and the healthcare system, and insurance companies. 3:19:25 Kenneth Frazier: If you went back a few years ago, when we negotiated to get our drugs on formulary, our goal was to have the lowest copay by patients. Today the goal is to pay into the supply chain the biggest rebate, and so that actually puts the patient at a disadvantage since they're the only ones that are paying a portion of the list price. The list price is actually working against the patient. 3:19:50 Sen. Steve Daines (R-MT): Why do we have a system today? Where you all are setting, I'll just say very, very high list prices, which is the starting point for negotiation. Why? Olivier Brandicourt: Senator, we're trying to get formulary position. With those list prices. High list price, high rebates. It's a preferred position. Unfortunately the preferred position doesn't automatically ensure affordability at the end. Kenneth C. Frazier: Senator, If you bring a product to the market with a low list price in this system, you get punished financially and you get no uptake because everyone in the supply chain makes money as a result of a higher list price. Drug Pricing in America: A Prescription for Change, Part III April 9, 2019 Senate Committee on Finance Witnesses: Steve Miller, MD, Former Executive Vice President and Chief Clinical Officer, Cigna Corporation Derica Rice, Former Executive Vice President and President, CVS Health and CVS Caremark William Fleming, Pharm.D., Segment President, Healthcare Services, Humana Inc. John Prince, Chief Executive Officer, OptumRx Mike Kolar, JD, Interim President & CEO, Senior Vice President and General Counsel, Prime Therapeutics LLC Clips Sen. Ron Wyden (D - OR): Pharmaceutical Benefit Managers first showed up decades ago, back when prescription drugs were being utilized more extensively. The PBMs told the insurance companies, “we're the ones who know drug pricing, we will handle the negotiations for you.” But there is little evidence that the pharmaceutical benefit managers have actually held down the prices in a meaningful way. In fact, most of the evidence shows just the opposite. Pharmaceutical Benefit Managers actually make more money when they pick a higher price drug over a lower price drug. Colleagues, let's remember that all the way through this discussion, benefit managers make more money when they pick a higher price drug over a lower price drug. The logic on this isn't exactly complicated, graduate-level economics. PBM profits are based on taking their slice of the prescription-drug pie. More expensive drugs means there's a bigger pie. When there's a bigger pie, [there are] bigger slices for the pharmaceutical benefit managers. 50:24 Mike Kolar: Rebates and the role they play have been key areas of focus in the drug cost debate. In our view, rebates are a powerful tool to offset high prices, which are set by pharmaceutical companies, and pharmaceutical companies alone. The fact that rebates are not offered on many of the highest cost drugs, and that studies show no correlation between prices and rebates underscore that rebates are a key to mitigating rather than causing high drug prices. We pass rebates through fully to our plans, and we believe our plans should be able to choose how to apply these rebates in ways that best serve their members and market needs by balancing premiums and cost sharing. 56:05 Sen. Chuck Grassley (R-IA): I'd like to talk about consolidation, including the recent integration of PBMs with insurance companies. Last year I wrote to the Justice Department on the issues, it reported that the three largest PBMs who are before us today now covers 71% of Medicaid, Medicare Part D enrollees and 86% of standalone Drug Plan enrollees. 57:45 Derica Rice: This is a highly competitive space. In addition to the three that you've pointed out here, CMS has noted there are over 60 PBMs across the US. Therefore, the competition, there's many options for the employers that are out there, government entities, as well as unions to choose from given their specific needs. 1:10:35 Sen. Debbie Stabenow (D-MI): So when we look at Express Scripts has 100 million Americans covered, CVS 90 million, OptumRx 65 million, Prime Therapeutics 27 million, Humana 21 million, and yet Americans still pay the highest prices in the world. Even though you are negotiating for millions of people. The VA has its own pharmacy benefit manager service, they negotiate for 9 million veterans, and they pay, on average, 40% less for the same drugs that the rest of the healthcare system pays for. Despite greater volume, you are unable to secure these kinds of low prices. With all due respect, you guys are pretty bad negotiators. Given the fact that the VA can get 40% less. And so I'd like to know from each of you why that's the case. Dr. Miller? Steve Miller [Former EVP and Chief Clinical Officer, Cigna Corporation]: Yes. Part of the equation is giving patients choice. At the VA, they actually limit their formulary more than any of us at this table do. So oftentimes, they'll have one beta blocker, one ace inhibitor. And so if it's going to get to that level of choice, then we could get better prices also. Sen. Stabenow: Let me jump in, in the interest of time. I know you create nationwide drug formularies, you have pre-authorization, you give preferred status to certain medications. So you don't use any of those tools that the VA is using? Because you do. Steve Miller: We definitely use those tools, but we also give people choice. It's crucial for both physicians and patients to have the choice of the products they want to be able to access. Many of our plans want us to have broad formularies and when you have more products, it means you move less market share. Sen. Stabenow: So basically you're saying a 40% premium gives them more choice. 1:24:30 Sherrod Brown (D-OH): If the administration's rebate rule were finalized as proposed, would you in some way be required to change the way you do business? Mike Kolar: Yes, Senator we would. John Prince: Yes. William Fleming: Yes. Derica Rice: Yes. Steve Miller: Yes. Sen. Brown: Thank you. 1:25:05 Sherrod Brown (D-OH): What percentage of prescriptions that you fill across Part D actually receive a rebate? Roughly what percentage? Mike Kolar: So Senator, approximately 8% of the prescriptions that we cover in Part D are associated with a rebate. Sen. Brown: Okay, Mr. Prince? John Prince: Senator, I don't know the exact number, I know our overall business is about 7%. Sen. Brown: Okay, thank you. William Fleming: About 7-8%. Derica Rice: Senator, I do not know the exact number but we pass through 100% of all rebates and discounts. Sen. Brown: [Grunt] Steve Miller: 90% of the prescriptions will be generic. Of the 10% that are branded, about two-thirds have rebates. So it's about seven-- Sen. Brown: 7-8% like the others. Okay. To recap, PBMs do not set drug prices. Forcing you to change the way you do business -- as the administration's rule would — will not change that fact. And while the rule might impact a small percentage of drugs and Part D that receive a rebate, it does nothing to lower costs, as your answer suggests, for the other 90% of prescriptions you fill. Most importantly, absolutely nothing in the proposed rule would require Secretary Azar's former employer or any other pharma company to lower the price of insulin or any other drug. It's important to establish that, so thank you for that. 1:41:40 Catherine Cortez Masto (D-NV): Let me ask you, Dr. Fleming, in your testimony, you say Humana's analysis of the rebate rule -- and we're talking about the administration's rebate rule now — found that approximately 17% of beneficiaries will see savings at the pharmacy counter as a result of this rule. Can you tell me a little bit more about who these people are? And what kind of conditions do they have? William Fleming: Senator, there will be a number of members who are taking brand drugs for which we get rebates and so it could vary all the way from the common chronic conditions, things like diabetes or hypertension or high cholesterol, all the way over to occasionally, not usually, but occasionally on the specialty drug side. When you think of some medications like treatments for rheumatoid arthritis, multiple sclerosis, places where there's competition. Cover Art Design by Only Child Imaginations Music Presented in This Episode Intro & Exit: Tired of Being Lied To by David Ippolito (found on Music Alley by mevio)

Manejamos Jetta comfortline 2022 y Acura RDX 2022 te contamos todo sobre estos autos, y te platicamos que próximamente estaremos en INA PAACE Automechanika con Refaccionaria APYMSA

Acura se equipa con Borla, llega Cavalier 2023, Ford deja sus agencias y se muda a digital, Lexus NX 2022

In questo episodio Giuseppe Riefolo viene intervistato da Gaetano Pellegrini sui contenuti al centro del suo articolo intitolato: “L'analista curioso. La curiosità agita dall'analista e il processo di enactment”, pubblicato sul volume 1/2022 della Rivista di Psicoanalisi.Link per scaricare l'articolo: https://riviste.raffaellocortina.it/scheda-articolo_digital/giuseppe-riefolo/lanalista-curioso-la-curiosita-agita-dallanalista-e-il-processo-di-enactment-RDPS2022_1_4-3726.htmlGiuseppe Riefolo, psichiatra, è membro ordinario della Società Psicoanalitica Italiana. Ha lavorato presso il  DSM della ASL RM.1 fino al settembre 2019.. Ha collaborato con l'istituto di Psichiatria dell'Università Cattolica del S. Cuore di Roma  e con quello dell'Università G. D'annunzio di Chieti dove ha insegnato presso la scuola di specializzazione in Psichiatria. Effettua seminari e supervisioni cliniche presso diversi Dipartimenti di Salute Mentale. E' presidente dell'associazione SMES-ITALIA, che si occupa di promozione sociale costituita da esperti e professionisti che lavorano in prima linea con persone senza dimora e con problemi di salute mentale. Conduce dal 2018 un “gruppo terapeutico aperto” per persone Senza Dimora, presso la Stazione Termini di Roma in collaborazione con l'associazione “Binario 95”.Ha pubblicato circa 170 articoli e 14 monografie in tema di psicoanalisi e psichiatria ed una monografia in tema di storia dell'arte (con Filippo Maria Ferro). Sul piano della ricerca si è occupato di Storia della psichiatria sia riguardo alle istituzioni manicomiali che di temi di psicopatologia classica. In questa linea con Filippo Maria Ferro ha pubblicato "Figure dell'isteria" (Metis, 1996); “Isteria e campo della dissociazione” (Borla, 2006) ed una serie di  note relative a particolari personaggi della psichiatria classica quali, Sementini, Chiarugi, Clérambault.Parallelamente a temi di carattere storico, si è occupato dell'analisi dinamica delle istituzioni territoriali con il volume: "Psichiatria Prossima. La psichiatria territoriale in un'epoca di crisi" (Bollati Boringhieri, 2001) e con Giuseppe Leo, “Psicoanalisi e luoghi della riabilitazione” (Frenis Zero, 2013). Sul tema dell'uso del cinema in psicoanalisi e in psichiatria, ha pubblicato “Le visioni di uno psicoanalista” (Antigone, Torino, 2006 e 2009) e “il film di cinquanta minuti” Metis, 2015. Con Paolo Boccara sullo stesso tema ha pubblicato “Al cinema dallo psicoanalista” (Borla, 2015). Ultimamente con Paolo Boccara e Gianfranco Meterangelis ha curato il volume: “Enactment. Parola e azione in psicoanalisi” (Franco Angeli, 2019). Con Giuseppe Leo ha curato il volume “Enactment in Psychoanalysis” (Frenis Zero, 2019) recentemente (2022) pubblicato anche in italiano. Ha insegnato presso la sezione romana della Società Italiana di Psicoterapia Psicoanalitica e insegna tuttora presso la scuola di formazione Scuola Internazionale di Psicoterapia nel Setting Istituzionale di Roma.link al volume 1/2022: https://riviste.raffaellocortina.it/scheda-fascicolo_contenitore_digital/autori-vari/rivista-di-psicoanalisi-2022-1-RDPS2022_1-3722.htmlI singoli articoli e i diversi volumi della Rivista di Psicoanalisi sono disponibili al sito dell'editore riviste.raffaellocortina.itUlteriori riferimenti bibliografici:“Parsons, M.(2006). The Analyst's Countertransference to the PsychoanalyticProcess1. Int. J.Psycho-Anal., 87(5):1183-1198”“Kravis, N.(2013). The Analyst's Hatred of Analysis. Psychoanal. Q.,82(1):89-114”

Te decimos quien se gano 1,500USD en producto Borla, hoy sin el Ratón nos toca improvisar y hablamos de cuánto costaba un auto antes vs cuanto cuestan ahora y para finalizar Jorge nos cuenta la historia de su Chevy.

The guys receive special access to visit Borla's R&D facility in Oxnard, California and get a behind-the-scenes look at what goes into the development and creation of an aftermarket exhaust system, with David Borla himself.

BJ Killeen – Automotive Journalist and Voice of Reason is back and she and Alan share their frustrations in dealing with the maintenance of their vehicles. Alan talk’s about turning Patrick Swayze’s 1990 Range Rover into an electric vehicle. He... The post We Say Goodbye to Friend and Life Long Auto Enthusiast Alex Borla; Introducing the 2023 Nissan Z| #493 appeared first on THE DRIVE with Alan Taylor.

Esta semana falamos sobre o Burger King que oferece NFTs, o impacto do novo iOS15 da Apple para os marketers e por último, como está o Instagram afetar os adolescentes. Download do podcast [TEMAS DA SEMANA] MIGUEL Uma nova técnica de merchandising…À BORLA! https://www.marketingdive.com/news/burger-king-introduces-keep-it-real-meals-after-banning-120-artificial-ingr/606283/   DIOGO A atualização do iOS 15 foi lançada e os […] O conteúdo Burger King e NFTs, a Apple e o impacto do iOS15 e como o Instagram afeta crianças – e35s01 aparece primeiro em Marketing por Idiotas.

Dave Borla joins Adam and Matt to talk about all things exhaust. Matt recalls his tour of Roush headquarters and the guys share simple suggestions on how car companies can improve cars.Hosts: Adam Carolla and Matt D'AndriaProducer: Chris LaxamanaEngineer: Caelan Biehn